New hope for rare blood cancers: fedratinib trial shows promise
NCT ID NCT05177211
First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 32 times
Summary
This study tests a drug called fedratinib in 25 adults with rare blood cancers (MDS/MPN and chronic neutrophilic leukemia). The goal is to see if the drug can shrink enlarged spleens and improve blood counts. Fedratinib is taken as a pill and works by blocking certain signals that help cancer cells grow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.